News coverage about Novus Therapeutics (NASDAQ:NVUS) has trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novus Therapeutics earned a coverage optimism score of 0.07 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.0776031987825 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Novus Therapeutics (NASDAQ:NVUS) traded down $0.11 on Monday, hitting $3.87. The stock had a trading volume of 4,900 shares, compared to its average volume of 19,101. Novus Therapeutics has a twelve month low of $3.42 and a twelve month high of $10.98.
Novus Therapeutics (NASDAQ:NVUS) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://weekherald.com/2017/12/25/novus-therapeutics-nvus-earning-somewhat-favorable-press-coverage-report-finds.html.
Novus Therapeutics, Inc, formerly Tokai Pharmaceuticals, Inc, is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities.
Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.